Neoadjuvant chemotherapy for pediatric osteosarcoma patients

Area of Science:

• Pediatric Oncology
• Medical Chemotherapy
• Cancer Research

Background:

• Osteosarcoma survival rates have improved significantly since 1977 due to intensive chemotherapy.
• Current cure rates exceed 60%, driven by regimens including doxorubicin, high-dose methotrexate, and cisplatin.
• Focus is shifting towards improving quality of survival, including limb salvage surgery.

Purpose of the Study:

• To evaluate factors influencing chemotherapy efficacy in pediatric osteosarcoma.
• To identify optimal chemotherapy regimens for improved survival rates.
• To determine the impact of specific drug combinations and dose intensity.

Main Methods:

• Retrospective analysis of three chemotherapy regimens in 67 pediatric osteosarcoma patients.
• Regimens included combinations of doxorubicin, high-dose methotrexate, cisplatin, and ifosfamide.
• Patients were categorized into OOS-A (methotrexate, doxorubicin), OOS-B (OOS-A + cisplatin), and OOS-C (OOS-B + ifosfamide) groups.

Main Results:

• The OOS-A regimen showed the lowest survival rate (40.6%).
• OOS-B (67.5%) and OOS-C (72.5%) regimens demonstrated significantly higher survival rates (P < 0.001).
• No significant difference in survival was observed between OOS-B and OOS-C; higher relative dose intensity in OOS-B correlated with better prognosis.

Conclusions:

• Doxorubicin, high-dose methotrexate, and cisplatin are potent chemotherapeutic agents for osteosarcoma.
• Maintaining the dose intensity of established regimens is more critical for improving survival than adding new drugs.
• Optimizing existing chemotherapy protocols can lead to better outcomes in pediatric osteosarcoma patients.